- Home
- DMAC vs IGA Comparison
DMAC vs IGA Comparison
Compare DMAC & IGA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DMAC
- IGA
- Stock Information
- Founded
- DMAC 2000
- IGA 2005
- Country
- DMAC United States
- IGA United States
- Employees
- DMAC N/A
- IGA N/A
- Industry
- DMAC Biotechnology: Pharmaceutical Preparations
- IGA Investment Managers
- Sector
- DMAC Health Care
- IGA Finance
- Exchange
- DMAC Nasdaq
- IGA Nasdaq
- Market Cap
- DMAC 260.0M
- IGA 151.0M
- IPO Year
- DMAC N/A
- IGA N/A
- Fundamental
- Price
- DMAC $4.45
- IGA $9.66
- Analyst Decision
- DMAC Strong Buy
- IGA
- Analyst Count
- DMAC 4
- IGA 0
- Target Price
- DMAC $10.75
- IGA N/A
- AVG Volume (30 Days)
- DMAC 393.5K
- IGA 42.3K
- Earning Date
- DMAC 08-06-2025
- IGA 01-01-0001
- Dividend Yield
- DMAC N/A
- IGA 8.93%
- EPS Growth
- DMAC N/A
- IGA N/A
- EPS
- DMAC N/A
- IGA N/A
- Revenue
- DMAC N/A
- IGA N/A
- Revenue This Year
- DMAC N/A
- IGA N/A
- Revenue Next Year
- DMAC N/A
- IGA N/A
- P/E Ratio
- DMAC N/A
- IGA N/A
- Revenue Growth
- DMAC N/A
- IGA N/A
- 52 Week Low
- DMAC $3.19
- IGA $7.77
- 52 Week High
- DMAC $6.82
- IGA $8.88
- Technical
- Relative Strength Index (RSI)
- DMAC 53.15
- IGA 34.28
- Support Level
- DMAC $4.81
- IGA $9.67
- Resistance Level
- DMAC $5.60
- IGA $9.85
- Average True Range (ATR)
- DMAC 0.49
- IGA 0.09
- MACD
- DMAC 0.05
- IGA -0.01
- Stochastic Oscillator
- DMAC 43.21
- IGA 9.52
About DMAC DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.
About IGA Voya Global Advantage and Premium Opportunity Fund of Beneficial Interest
Voya Global Advantage and Premium Opportunity Fund is a United States-based diversified, closed-end management investment company. The fund has two investment objectives. Its primary objective is to provide a high level of income, while the secondary objective is to seek capital appreciation. To achieve these objectives, the fund invests at least 80% of its managed assets in a portfolio of common stocks from various countries around the world, including the United States. Additionally, it uses an integrated derivatives strategy.